4259083553

. **?***:

FEB 2 5 2005

RECEIVED

CENTRAL FAX CENTER

PTC/S8/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/787,385 TRANSMITTAL Filing Date 2/26/04 FORM Inventor Steven C. Quay et al. (to be used for all correspondence after Initial filing) Art Unit 1623

		Examiner Name				
Total Number of Pages In This Submis	ssion 4	Attorney Docket Number	03-02US			
	ENC	LOSURES (Check all that apply				
		Check an that apply				
Fee Transmittal Form		Drawing(s)	After Allowance communication to Technology Center (TC))		
Fee Attached \$65		Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences	,		
Amendment / Reply		Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief	n		
Request to Correct F	Priority	Petition to Convert to a Provisional Application	Proprietary Information			
Affidavits/declaration	(3)	Declaration and Power of Attorney, Declaration, 2 pages	Status Letter			
Extension of Time Requesi		Terminal Disclaimer	Other Enclosure(s) (please identify below):			
Express Abandonment Req	uest	Request for Refund	Substitute page one of form 1449A/PTO			
Substitute Information Disclosure Statemer		CD, Number of CD(s)				
Certified Copy of Priority Document(s)		We recently filed an IDS of 3 pages with references on 1/14/2005. We noted a typographical error on page 1. The				
Response to Missing Parts/ Incomplete Application Mayor Pharmaceutical Laboratories US patent number ha			e			
Response to Missing Pa	rts been	corrected from A 500 044	ones us patent number has	3		
under 37 CFR 1.52 or 1.	53 0645	25 244 Kindle 2014	to the correct patent number	er		
		of 4,525,341. Kindly switch out the prior page one of form				
1449A/PTO for this new page one. Thank you.						
	PICNATURE:	OF APPLICANT ATTENDED				
F1		OF APPLICANT, ATTORNEY, OR				
or Nastech Pharma	ceutical Compar	al Company Inc., Paul G. Lunn, Attorney, Registration No. 32,743				
Individual name	\mathcal{L}					
Signature	Yund	P.Z				
Date February 25, 200	5					
	CERTIFIC	ATE OF TRANSMISSION/MAILIN	łG			

I hereby certify that this correspondence is being facsimile transmitted to the USPTO to the Fax number 703-872-9306 on the data shown Typed or printed name Jeffrey L. Granger Signature Date February 25, 2005

This collection of information is conjuged by 3 (GFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application Confidentiatily is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual company, accounts gamening, preparing, and summing the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commissions P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450.

FEB 2 5 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Quay et al.

Attorney Docket No.: 03-02US

Serial No.: 10/787,385

Group Art Unit: 1623

Filed: 2/26/2004

Title: CYANOCOBALAMIN LOW

VISCOSITY AQUEOUS FORMULATIONS FOR INTRANASAL DELIVERY Examiner: unknown

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUBSTITUTE INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

- X under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- under 37 CFR 1.97(c) together with either a:
 - ___ Statement under 37 CFR 1.97(e), or
 - a \$180.00 fee under 37 CFR 1.17(p), or
 - (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- under 37 CFR 1.97(d) together with a:
 - ___ Statement under 37 CFR 1.97(e), and
 - a \$180.00 fee set forth in 37 CFR 1.17(p).
 - (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant(s) submit herewith a substitute Form PTO 1449-Information Disclosure Citation page one only.

Applicants also wish to bring to the attention of the Examiner that the assignee previously prosecuted patent application no. 06/723,859, entitled "Aerosol Compositions for Nasal Delivery of Vitamin B12," filed April 16, 1985, which was abandoned by the assignee.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

I hereby certify that this Correspondence is being facsimile transmitted to the USPTO at fax number 703-872-9306, on the date indicated below.

Date of Deposit: February 25, 2005

Typed Name: Jeffrey L. Granger

Gionahma

Respectfully submitted,

Paul G. Lunn

Attorney/Agent for Applicant(s)

Reg. No. 32743

Date: February 25, 2005

Telephone No.: (425) 908-3643

业于。"

PTO/SB/08a (09-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB of

			THESE YEARS A VALUE OWN CONTROL TO THE SECOND CONTROL TO THE SECON		
Substitute for form 1449A/PTO			Complete If Known		
ı			Application Number	10/787,385	
I	INFORMATION DISCL	OSURE	Filing Date	2/26/2004	
ł	STATEMENT BY APPLICANT		First Named Inventor	Quay et al.	
ı			Art Unit	1623	
(Use as many sheets as necessary)		sary)	Examiner Name		
Ł	Sheet 1	of 3	Attorney Docket Number	03-02US	

			U.S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.	Number - Kind Code ² (IF known)	Issued Date MM-DO-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
·····	<u> </u>	US- 2,703,302	03-01-1955	Merck & Co. Inc.	
·		US- 2,703,303	03-01-1955	Marck & Co., Inc.	
		US- 2,748,798	05-22-1956	The Pharma-Craft Corporation	
		US- 2,914,222	11-24-1959	Philip Mashberg	
		US- 3,000,793	09-19-1961	Merck & Co., Inc.	
		US- 2,951,017	08-30-1960	The Distillers Company Limited	
		US- 3,057,851	10-09-1982	Amour Pharmaceutical	
		US- 3,018,225	01-28-1962	Merck & Co., Inc.	700 The control of th
		US- 3,120,509	02-04-1984	Hoffmann-La Roche Inc.	
		US- 3,282,781	11-01-1966	Merck & Co., Inc.	
,		US- 3,548,057	12-15-1970	Merck & Co., Inc.	
		US- 3,577,537	05-04-1971	Merck & Co., Inc	
		US- 3,584,115	06-08-1971	Arthur I. Gebhart & Angelo T. Bonduris	
		US- 3,957,966	05-18-1976	GAF Corporation	
		US- 4,174,295	11-13-1879	Montedison S.p.A.	
		US- 4,525,341	08-25-1985	Mayor Pharmaceutical Laboratories	
	I	US- 4,724,231	02-09-1988	Nastech Pharmaceutical, Inc.	
		US- 5,801,161	09-01-1999	Merkus, Franciscus	
		US- 5,797,390	08-25-1998	McSoley, Thomas E	
		US- 5,925,625	07-20-1999	Merkus, Francicus	
		US- 6,885,421	12-16-2003	Image Therm Engineering, Inc.	

	,	FOREIG	N PATENT DOC	UMENTS		_
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ - Number - Kind Code ⁵ (if known)	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages or Relevant Figures Appear	тв
	-	EP 0131315 A2 EP 0130550 A2 PCT WO 86/05888 (International Application Number PCT/US88/00793)	02-15-1984 06-27-1984 10-23-1986 Publication Date	Istituto De Angell Instarmedical GmbH Nastech Pharmacautical Company, Inc.	re Manager Lifthes Whorst	
		PCT WO 88-05987 (International Application Number PCT/US86/00665)	10-23-1986 Publication Date	Nastach Pharmaceutical Company, Inc.		\vdash
		7/2				

Examiner Date Signature

Expressive | Considered | Consi

Transistion is attached.

Transistion is attached.

Transistion is attached.

Transistion is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information officer, U.S. Patent and Tradermark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.